Merus’ (MRUS) “Buy” Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Merus (NASDAQ:MRUS) in a report published on Friday,Benzinga reports. The brokerage currently has a $109.00 price target on the biotechnology company’s stock.

MRUS has been the topic of several other research reports. Wells Fargo & Company started coverage on Merus in a research note on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of Merus in a report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Piper Sandler initiated coverage on shares of Merus in a research report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective for the company. Finally, Citigroup increased their price objective on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $85.31.

Merus Trading Down 0.5 %

NASDAQ MRUS opened at $44.61 on Friday. Merus has a 12 month low of $37.77 and a 12 month high of $61.61. The stock has a 50-day simple moving average of $43.98 and a 200 day simple moving average of $46.03. The company has a market capitalization of $3.08 billion, a PE ratio of -11.29 and a beta of 1.15.

Merus (NASDAQ:MRUS) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. As a group, sell-side analysts predict that Merus will post -3.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Merus

A number of hedge funds have recently bought and sold shares of MRUS. FMR LLC grew its holdings in Merus by 0.4% during the 4th quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company’s stock worth $290,125,000 after acquiring an additional 25,595 shares during the period. Wellington Management Group LLP boosted its position in shares of Merus by 21.1% during the 4th quarter. Wellington Management Group LLP now owns 3,497,653 shares of the biotechnology company’s stock valued at $147,076,000 after purchasing an additional 610,139 shares in the last quarter. Franklin Resources Inc. grew its stake in Merus by 7.1% during the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company’s stock worth $117,722,000 after purchasing an additional 150,341 shares during the period. Avoro Capital Advisors LLC lifted its stake in Merus by 56.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company’s stock valued at $89,356,000 after buying an additional 770,000 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Merus in the fourth quarter valued at approximately $79,895,000. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.